• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Scientists pinpoint genetic target with promise for treating many forms of blindness


Investigators at Trinity College Dublin have highlighted the SARM1 gene, a key driver in the damage that ultimately leads to impaired vision.

The development of therapies for genetic forms of blindness can prove to be a challenge, primarily because they vary so widely, but scientists from Trinity College Dublin are highlighting a target with great promise for treating a number of these conditions.

The scientists have highlighted that a specific gene (SARM1) is a key driver in the damage that ultimately leads to impaired vision (and sometimes blindness), and—in a disease model—showed that deleting this gene protects vision after a chemical kick-starts the chain of dysfunction that mimics a host of ocular conditions.

According to a release from Trinity College Dublin, this means that therapies targeting suppression of SARM1 activity may hold the key to effective new options for treating a suite of diseases that can have a devastating impact on quality of life, and for many of which there are no treatment options currently available.

The scientists, led by a team from Trinity’s School of Genetics and Microbiology, recently published their findings in the International Journal of Molecular Sciences.1

According to lead author Laura Finnegan, a PhD candidate at Trinity, in response to injury SARM1 contributes to a process that leads to the degeneration of specialized cells and their axons in the eye.

“When this happens it essentially means that the optic nerve can no longer deliver signals from the eye to the brain,” she said in the release. “Impaired vision and blindness is extremely debilitating for millions of people across the globe, which is one of the main motivations for us to seek to better understand the genetic causes and, potentially, develop life-changing therapies.”

Moreover, Jane Farrar, a professor in Trinity’s School of Genetics and Microbiology and a senior author on the paper, noted in the release that another key finding was that visual function was still preserved when reassessed four months after SARM1 was deleted, indicating that the benefits can remain over time.

“This raises hopes that a targeted therapy delivered early enough may offer people diagnosed with an ocular neuropathy long-lasting preservation of sight,” Farrar said in the release. “We have a way to go before such a therapy is available but this work represents a significant step, sheds light on the pathway forward and offers hope that a range of diseases involving the optic nerve—from maternally inherited conditions such as Leber Hereditary Optic Neuropathy to the more commonly known glaucoma—will one day be treatable via such therapies.”

The research is the result of collaboration between Professor Farrar’s lab in the School of Genetics and Microbiology and that of Professor Andrew Bowie’s in the School of Biochemistry and Immunology in the Trinity Biomedical Sciences Institute.

It was funded by the Irish Research Council, Science Foundation Ireland, the Health Research Board of Ireland and Fighting Blindness Ireland.

1. Finnegan LK, Chadderton N, Kenna PF, et al. SARM1 ablation is protective and preserves spatial vision in an in vivo mouse model of retinal ganglion cell degeneration. Inter J Mol Sci. 2022;23(3):1606. doi: 10.3390/ijms23031606

Related Videos
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
Jay Barth, MD
Moving beyond the drop: CEO provides updates on Oyster Point's pipeline
Stargardt research: Therapy on the horizon for inherited retinal disease
© 2024 MJH Life Sciences

All rights reserved.